In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical ...

BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 The use of a regenerative medicine, specifically a CAR T-cell therapy, offers ...

B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...

B7-H3を標的とした抗体薬物複合体である抗B7-H3抗体薬物複合体ifinatamab deruxtecan（I-DXd、DS-7300）が、小細胞肺癌（SCLC）、食道扁平上皮癌（ESCC）、転移を有する去勢抵抗性前立腺癌（mCRPC）、扁平上皮非小細胞肺癌（sqNSCLC）を含む数多くの治療を受けた進行固形 ...

抗B7-H3抗体薬物複合体ifinatamab deruxtecan（I-DXd、DS-7300）が、難治性の小細胞肺癌（SCLC）に有効である可能性が長期観察でも ...

Breakthrough Therapy Designation is based on the encouraging survival data from the Phase 1 BrainChild-03 trial in children and young adults with diffuse intrinsic pontine glioma (DIPG) BrainChild Bio ...

GSK plc announced that its B7-H3-targeted antibody-drug conjugate GSK’227, now referred to by its International Nonproprietary Name, risvutatug rezetecan, has received Orphan Drug Designation (ODD) ...

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumours in the central nervous system (CNS), announced that the investigational B7-H3 targeting ...

Actinium Pharmaceuticals (NYSE American: ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa targeting B7-H3.